Showing 34,879 articles by Roger Pebody

Filters Author: Roger Pebody

Roger joined NAM in 2008 as an Editor and became Managing Editor in 2018. He is responsible for co-ordinating the editorial content of aidsmap.com, including news coverage and patient information materials. His involvement in HIV work began at Gay Men Fighting AIDS in the mid-1990s. Twitter: @RogerPebody

Pharmaceutical industry

Gilead sales of Hepatitis C drugs slump

Editor's pick
MarketWatch
2 November 2016
Undetectable viral load & treatment as prevention

Do people living with HIV who have an undetectable viral load need to wear condoms?

News
2 November 2016
The search for an HIV prevention vaccine

Explainer: the how, what and why of the latest HIV vaccine trial

Editor's pick
The Conversation
1 November 2016
PrEP

Europe’s authorities “are playing catch up” with the provision of PrEP claims new report

Editor's pick
Gay Times
1 November 2016
PrEP programmes & uptake

Electronic health records can help select candidates for HIV PrEP

News
1 November 2016
Pharmaceutical industry

Get ready for more drug ads: Facebook is making a bid for pharma dollars

Editor's pick
STAT
1 November 2016
Men who have sex with men (MSM)

Tanzania suspends some HIV programs for gay men, says health minister

Editor's pick
Thomson Reuters Foundation
1 November 2016
Global health targets

30000 Jamaicans must receive HIV/AIDS treatment to meet WHO guidelines

Editor's pick
Jamaica Observer
1 November 2016
Chemsex & recreational drug use

Most meth users too embarrassed to seek treatment

Editor's pick
University of Western Australia
1 November 2016
Tuberculosis & HIV

Underfunding ‘nightmare’ hampers the global TB battle

Editor's pick
Health-e
31 October 2016
Pharmaceutical industry

GSK discontinues development of maturation inhibitor BMS-986173

Editor's pick
HIV i-Base
31 October 2016
Side effects

Efavirenz Side Effects Include Suicide; It Could Have Been Me

Editor's pick
The Body
31 October 2016
Treatment simplification strategies

Darunavir/ritonavir & lamivudine matches triple-drug therapy

News
31 October 2016
PrEP

PrEP for African migrants in Europe? A research agenda

Editor's pick
The Lancet HIV (requires free registration)
31 October 2016
Drug-resistant TB

Early data indicates new regimen represents reprieve for patients with XDR TB

Editor's pick
Science Speaks
31 October 2016
Cancer

Only a small proportion of gay men with HIV receive anal cancer screening

News
31 October 2016
PrEP

Israeli Pilot Program Will Provide Free HIV-Prevention Medication to At-Risk Groups

Editor's pick
The Tower
31 October 2016
Harm reduction

'Fix rooms' plan for Glasgow drug addicts set for green light

Editor's pick
BBC Health
31 October 2016
Behaviour change interventions

Apps and Social Media Can Reach High-Risk HIV Populations

Editor's pick
Medscape (requires free registration)
31 October 2016
History of HIV & AIDS

Silence = Death: It’s Time to Teach AIDS History

Editor's pick
American Historical Association
31 October 2016
Harm reduction

Maintenance prescribing saves lives of English heroin addicts

Editor's pick
Drug & Alcohol Findings
30 October 2016
TB treatment

TB Alliance partners with PepsiCo to advance the fight for improved medicines for children

Editor's pick
TB Alliance
28 October 2016
New & experimental HIV treatments

New long-acting fusion inhibitor albuvirtide plus boosted protease inibitor matches standard triple-drug therapy

News
28 October 2016
Access to healthcare

Over 1 million treated with highly effective hepatitis C medicines

Editor's pick
World Health Organization
27 October 2016